Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01532791 · ClinicalTrials.gov registry record

Natural History Study - Mitochondrial Disease

A clinical trial of MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier, sponsored by Columbia University.

Recruiting
Registry status
300
Enrollment target
1
Study location

NCT01532791: Recruiting study of MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier, sponsored by Columbia University.

NCT01532791 is a study of MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier that is actively recruiting participants, run by Columbia University. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01532791, a study of MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
300 participants
Enrollment target
1
Study location

Study Summary

Carriers of the m.3242A\>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. The investigators would like to learn more about these disorders and have designed a "Natural History Study" to monitor these conditions over time so that physicians and scientists can not only understand the problems that patients have, but work on developing treatments. The focus of the current work is to evaluate known mutation carriers of the m.3243A\>G (mitochondrial DNA) and their maternal relatives (carrier status not a requirement for participation). Paternal relatives will serve as controls. This study involves no treatment.

Primary Outcome

Evaluate structure and function in brain and muscle

Study Locations (1)

New York

  • Columbia University - New York

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2004-07
Est. Completion 2026-07
Columbia University

958 total trials

What NCT01532791 shows while recruiting

NCT01532791 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.

The record links to 1 condition, with MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier appearing as the primary indexed condition, and to 0 interventions.

NCT01532791 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01532791 about?

NCT01532791 is a clinical study titled "Natural History Study - Mitochondrial Disease". Carriers of the m.3242A\>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. The investigators would like to learn more about these disorders and have designed a "Natural History Study...

What is the current status of trial NCT01532791?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2004-07. Estimated completion is 2026-07.

What conditions does trial NCT01532791 study?

This clinical trial studies the following conditions: MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier.

Who is sponsoring clinical trial NCT01532791?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01532791 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01532791, the US trial registry maintained by the National Library of Medicine. NCT01532791 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.